Consideration for the asymptomatic transmission of COVID-19: Systematic Review and Meta-Analysis

Khaiwal Ravindra^{1*}, Vivek Singh Malik^{1,2}, Bijaya K Padhi¹, Sonu Goel¹ and Madhu Gupta¹

 ¹Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India – 160012
 ²Department of Pediatrics, Advanced Pediatric Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India - 160012

Abstract:

Objective: Worldwide countries are experiencing viral load in their population, leading to potential infectivity of asymptomatic COVID-19. Current systematic review and meta-analysis aimed to investigate the role of asymptomatic infection worldwide reported in family-cluster, adults, children, health care workers, and travelers.

Design: Online literature search (PubMed, Google Scholar, medRixv, and BioRixv) was accomplished using standard Boolean operators, studies published till 07th June 2020.

Setting: Studies were included from case reports, short communication, and retrospective to cover sufficient asymptomatic COVID-19 transmission reported.

Participants: Familial-clusters, adults, children, health care workers, and travelers.

Results: We observed asymptomatic transmission among familial-cluster, adults, children, health care workers, and travelers with a proportion of 32% 37%, 26%, 6%, and 32%, respectively. This study observed an overall proportion of 31% (95%CI: 0.19-0.44) with heterogeneity of I^2 (97.28%, p=<0.001) among all asymptomatic populations mentioned in this study. Among children and healthcare workers, this study showed no heterogeneity; to overcome the interpretation from a fixed model, the random effect model was also applied to estimate the average distribution across studies included in the meta-analysis.

Conclusion: We found and suggest the rigorous epidemiological history, early isolation, social distancing, and increased quarantine period (at least 28 days) after screening asymptomatic cases as well as their close contacts for chest CT scan even after their negative nucleic acid testing to

minimize the spread among the community. This systematic review and meta-analysis support asymptomatic COVID-19 transmission between person to person depending on the variation of virus incubation period among individuals. Children especially, school-going aged <18 years, need to be monitored and prevention strategy, e.g., chest CT and social distancing required to prevent the community transmission of COVID-19 in asymptomatic mode.

Keywords: COVID-19, Asymptomatic transmission, CT scan, Age, Children.

***Corresponding author:** Prof. Ravindra Khaiwal, E-mail: khaiwal@yahoo.com, Tel.: +911722755262; fax: +911722744401.

Strengths and limitations of this study

- Examine the possibility of asymptomatic COVID-19 transmission in the community at different levels.
- Supports contact tracing, social distancing, early isolation, and increased quarantine period to minimize the risk of virus spread.
- Supports chest CT scan and viral nucleic acid testing to identify the asymptomatic cases in the community.
- Supports rigorous epidemiological history with multiple detection methods.
- A higher proportion of asymptomatic incidence was seen, suggests monitoring, and maintaining social distancing.

Introduction: Symptomatic viral infections have been a significant risk factor for the public. It is more concerned while asymptomatic viral infection occurs in the community. For symptomatic cases, fever, dyspnea, dry cough, and diarrhea are the major sign, and symptoms were reported lasting up to 14 days with a median incubation period 9-12 days. Aerosol transmissions occurred through sneezing or coughing and reported to be the primary route of infection from person to person¹. Simulation studies have been done and observed asymptomatic transmission among person-person². PCR-based assays were suggested in managing the asymptomatic transmission of the virus by carriers³. The first case of asymptomatic transmission of COVID-19 was reported by JAMA on 21st February 2020 by an asymptomatic carrier (He et al., 2020; Wang et al., 2020). Asymptomatic infection was reported as "hidden coronavirus infections" ("infections" or "covert coronavirus infections" ⁵. Asymptomatic COVID-19 cases should be quarantined for 14 days, and their nucleic acid test should be negative twice before discharging, which is mentioned in the COVID-19 prevention and control protocol (6th edition). Worldwide, interest in asymptomatic COVID-19 infections and their transmission potential has been increased ⁶. In China, around 86% asymptomatic COVID-19 transmission was undocumented before travel restrictions⁶.

Till now, asymptomatic COVID-19 cases have been reported among Familial-cluster ^{7–12}, pregnant women ^{13,14}, adults ^{15–24}, children ^{1,25,26}, health care worker ^{27–29}, and travelers ^{30–34}. Considering the potential transmission of asymptomatic COVID-19 among the community we tried to accumulate the desired information from the general population as well as vulnerable groups from the different backgrounds were taken, and meta-analysis was performed. There are no previous studies available for asymptomatic COVID-19 transmission among different subgroups between person-person.

Methods:

Search Strategy: For the meta-analysis PRISMA guideline was applied on this study ^{35,36}, Boolean operators "asymptomatic transmission", "((COVID-19) AND (Coronavirus)) AND (Asymptomatic transmission)", "((COVID-19) OR (Coronavirus)) AND (asymptomatic transmission)", "(SARS-CoV-2) AND (asymptomatic transmission)", "(2019-nCoV) AND (asymptomatic transmission)", "(Wuhan pneumonia) AND (asymptomatic transmission)", "(Wuhan flu) AND (asymptomatic transmission)", "(2019-nCoV acute respiratory disease) AND

(asymptomatic transmission)", "(2019-nCoV respiratory syndrome) AND (asymptomatic transmission)" used for the PubMed database, Google scholar, medRxiv, and BioRixv. The study included published literature without language restriction until 07th June 2020. Selection criteria (Inclusion/exclusion criteria): studies with the following conditions were included for the meta-analysis: (1) Case reports, case series, and cohort study, (2) Asymptomatic infection of COVID-19 (clinical, laboratory or both confirmed), and (3) Studies reporting cross-sectional were excluded.

Data extraction: Details of authors, sample size, and numbers reported for the asymptomatic infection of COVID-19 were extracted and recorded independently. Data extraction was done separately by two independent reviewers and disagreement was settled by joint discussion. To minimize the risk of duplication of data was carefully handled.

Quality assessment: The Newcastle Ottawa scale (cohort studies) was used to evaluate the selected studies in the current systematic review and meta-analysis ^{35,37}.

Publication bias: Possible publication bias was not calculated in this study as we have included cohort, case report study design to cover the possible asymptomatic cases considering the current situation causing limited power of the among studies ³⁸.

Statistical analysis and data synthesis: After extracting the results, studies were pooled, and the effect of asymptomatic transmission of COVID-19 was examined through the random effects method. For continuous outcome standard error (SE) with 95% CI was calculated. The heterogeneity (I^2 statistic) was assessed between studies. I^2 values the existence of heterogeneity was taken, as suggested by Higgins and colleagues ^{35,39,40}. Data for meta-analysis was accomplished as described by ^{35,41}.

Patient and public involvement:

There was no direct patient or public involvement in this systematic review and meta-analysis.

Results: Literature search: Literature search and screening were done according to the PRISMA chart (Figure: 1). Initially, 4,667 published research articles were identified using online database search. After the removal of 4617 Publications due to duplications, only 50

research articles were shortlisted, followed by further screened for relevance. Finally, 27 articles meeting the inclusion criteria were grouped into the family-cluster (total studies: 06), Adults (total studies: 10), Children (total studies: 03), health care workers (total studies: 03), and travelers (total studies: 05) were included in the quantitative synthesis of the current study.

Characteristics of the Study: The main components of the studies are summarized (Table 1). All published research articles fall under the cohort (observational) study design. Most of the studies are from China, Korea, USA, Japan, and Germany. The study included articles published/available online till 07th June 2020.

Author	Country	Age, years (mean (±SD)/ median(IRQ)	Study Type	Type of test	Major findings
Family cluster					
Jasper Fuk- woochan	China	Family: 36-60 Child: 10	Cohort	RT-PCR	Supports person to person transmission between family
Ming Chen	China	8.5 ± 0.17	Case report	RT-PCR	The ability of COVID-19 transmission during the asymptomatic period even after negative viral testing
Shubia Lu	China	8	Case report	RT-PCR	Supports rigorous investigation in the combination of various testing methods to for asymptomatic COVID-19 cases
GuoaingQian	China	6	Brief report	RT-PCR	Variation in clinical manifestation across individuals was observed
Feng Ye	China	38 ± 18.38	Cohort	RT-PCR	Possibility of COVID-19 transmission by the asymptomatic carrier during the incubation period
Yan Bai	China	20	Cohort	RT-PCR	Support asymptomatic transmission through a family contact
Adults					
SijiaTian	China	47.5	Cohort	RT-PCR	Early isolation and quarantine for close contacts to prevent asymptomatic transmission
Gu. Kim	Korea	26 (22-47)	Research note	RT-PCR	Supports social distancing to prevent asymptomatic

Table 1: Characteristics of the study participants

					transmission
Wei Fang Kong	China	37.7 (±19)	Cohort	RT-PCR	Suggest rigorous epidemiological history and chest CT scan as a practical tools to identify the asymptomatic COVID-19 cases in the community
Guosheng Yin	China	-	Cohort	RT-PCR	No difference in the transmission rate of COVID-19 between asymptomatic and symptomatic cases
HengMeng	China	42.60 (±16.56)	Cohort	RT-PCR	Suggest chest CT scan as an important tool to screen the asymptomatic COVID-19 cases in the community
Farida Ismail AI Hosani	UAE	37 (30-45)	Cohort	RT-PCR	No transmission among household contacts after the implication of strong isolation policies
Daihie He	China	-	Cohort	RT-PCR	Significantly smaller transmissibility of asymptomatic cases than symptomatic
ChengfengQiu	China	43 (8-84)	Cohort	RT-PCR	Transmission occurred after 14 days quarantine periods, suggests
Rui Zhou	China	-	Short communication	RT-PCR	Suggest rigorous epidemiological history and nucleic acid testing
Shin Young Park	Korea	38 (20-0)	Report	RT-PCR	Supports contact tracing, testing and increasing quarantine to prevent asymptomatic COVID- 19 transmission in the community
Children					
Zhiliang Hu	China	<15	Cohort	RT-PCR	Suggest close contact tracing, and nucleic acid testing to identify the asymptomatic COVID-19 tracing the community
HaiyanQiu	China	8.3 (±3.5)	Cohort	RT-PCR	Possibility of asymptomatic COVID-19 transmission by close contacts
Xin Tan	China	-	Cohort	RT-PCR	Possibility of asymptomatic COVID-19 transmission by intra familial contact
Health Care W	orkers		t.	1	

Anne Kimball	USA	-	-	RT-PCR	Reported rapid transmission among health care worker
Vera Schoierzeck	Germany	48	Cohort	RT-PCR	Suggest nucleic acid testing for asymptomatic COVID-19 cases
Jose Lucar	USA	>18	Cohort	RT-PCR	transmission reported because of prolonged surgery done on asymptomatic COVID-19 case
Traveler>18					
COVID-19 Team, Korea	Korea	>18	Cohort	RT-PCR	Supports asymptomatic transmission with minor symptoms
Kenji Mizumoto	Japan	>18	Rapid communication	RT-PCR	Support social distancing to prevent the asymptomatic transmission
Ren Wan	China	>18	Short communication	RT-PCR	Possibility of asymptomatic transmission after 14 days quarantine from asymptomatic COVID-19 case
Justin WONG	Brunei	-	Rapid communication	RT-PCR	Support social distancing & nucleic acid testing of asymptomatic COVID-19 case
ThiQuynh Mai Le	China	-	Abstract	-	Support asymptomatic COVID- 19 viral transmissibility in the absence of signs and symptoms

Note: -: Missing values (mean/median values were not reported)

Quality assessment: The Newcastle Ottawa Scale (for cohort studies) was used for qualitative evaluation of the studies included in the meta-analysis ^{35,37}. The risk of bias was assessed based on three domains (selection, comparability, and outcome), as highlighted (Table 2).

Table 2: Quality assessment: Cohort study quality according to the Newcastle-Ottawa scale

Study	Selec	tion***	***		Comparability**	Outco	me*****		Total quality score
	1	2	3	4	5	6	7	8	
Family cluster	,		,	1	1		1		l.
Jasper Fuk-woochan	*	0	*	0	*	*	0	0	4
Ming Chen	*	0	*	0	0	*	0	0	3
Shubia Lu	*	0	*	0	0	*	0	0	3
GuoaingQian	*	0	*	0	0	*	0	0	3
Feng Ye	*	0	*	0	0	*	0	0	3
Yan Bai	*	0	*	0	0	*	0	0	3
Adults					L				
SijiaTian	*	0	*	0	0	*	0	0	3
Gu. Kim	*	0	*	0	0	*	0	0	3
Wei Fang Kong	*	0	*	0	0	*	0	0	3
Guosheng Yin	*	0	*	0	0	*	0	0	3
HengMeng	*	0	*	0	0	*	0	0	3
Farida Ismail AI Hosani	*	0	*	0	0	*	0	0	3
Daihie He	*	0	*	0	0	*	0	0	3
ChengfengQiu	*	0	*	0	0	*	0	0	3
Rui Zhou	*	0	*	0	0	*	0	0	3
Shin Young Park	*	0	*	0	0	*	0	0	3
Children	,		,					·	
Zhiliang Hu	*	0	*	0	0	*	0	0	3
HaiyanQiu	*	0	*	0	0	*	0	0	3
Xin Tan	*	0	*	0	0	*	0	0	3
Health Care Workers									
Anne Kimball	*	0	*	0	0	*	0	0	3
Vera Schoierzeck	*	0	*	0	0	*	0	0	3
Jose Lucar	*	0	*	0	0	*	0	0	3
Traveler	,		,					·	
COVID-19 Team, Korea	*	0	*	0	0	*	0	0	3
Kenji Mizumoto	*	0	*	0	*	*	0	0	4
Ren Wan	*	0	*	0	0	*	0	0	3
Justin WONG	*	0	*	0	0	*	0	0	3
ThiQuynh Mai Le	*	0	*	0	0	*	0	0	3

Note: Selection; 1) Representativeness of the exposed cohort, 2) Selection of the non-exposed cohort, 3) Ascertain exposure, 4) Demonstration that outcome of interest was not present at the start of study; **Comparability;** 5) Comparability of cohorts based on the design or analysis controlled for confounders; **Outcome:** 6) Assessment of outcome, 7) Was follow-up long enough for outcomes to occur, 8) Adequacy of follow-up of cohorts.

Publication bias: This study included studies published as well as unpublished literature on MedRxic and BioRiv, as long as it meets study inclusion criteria.

Meta-analysis: The outcomes of the current meta-analysis (Table 3) and forest plot of asymptomatic positivity of COVID-19 among population (Figure 2) and different sub-groups (Figure 3) are shown. A random-effects model was used for the reported asymptomatic COVID-19 transmission at different levels in the community. Current meta-analysis observed heterogeneity among familial-clusters with $I^2 = 46.02\%$, p=0.0.10 with proportion of 32%(95%CI=(0.09-0.59), adults (aged >18 years) $I^2=98.44\%$, p=<0.001 with proportion of 37% (95% CI: 0.19-0.57). Travelers $I^2 = 98.18\%$, p = <0.001 with proportion of 32% (95% CI = 0.06-0.65), this study did not observed any heterogeneity among children and health care workers but the proportion of asymptomatic transmission was seen with rate of 26% (95%CI: 0.16-0.37) and 6% (95%CI: 0.00 - 0.31) respectively with overall heterogeneity of I² = 97.28%, p=<0.001. We didn't observe any significant difference of heterogeneity between groups (p=0.538). With no heterogeneity among children and health care workers random effect model observed an overall proportion of 26% and 6%, respectively. The likelihood ratio (LR) test was applied for random effect vs. fixed effect model to check the weighted difference (Figure 4). This study observed a proportion of 25% (95%CI: 0.17 - 0.35), chi-square value 129.9, p=<0.0001 of asymptomatic positivity of COVID-19 among the population.

Risk factor (Asymptomatic) Group	Studies	Asymptomatic Population (n)	Total Sample Size (N)	Proportion (95%CI)	I ²
Family Cluster	6	9	31	0.32 (0.09-0.59)	46.02%, p=0.10
Adults (>18 years age)	10	374	1688	0.37 (0.19-0.57)	98.44%, p=<0.001
Children (<18 years age)	3	36	73	0.26 (0.16-0.37)	-
Health Care Workers	3	13	125	0.06 (0.00-0.31)	-
Travelers	5	368	876	0.32 (0.06-0.65)	98.18%, p=<0.001
Combined (groups)	27	813	2793	0.31 (0.19-0.44)	97.28%, <0.001

 Table 3: The meta-analysis of asymptomatic transmission for COVID-19 among different sub-groups of the population:

Discussion: The current study summarized available retrospective studies, case reports from family-cluster, adults, children, health care workers, and travelers. Person to person asymptomatic transmission was observed among familial-cluster in an asymptomatic COVID-19 child aged ten years showed abnormal chest CT and another child with mild chest CT manifestation when his family members were diagnosed COVID-19 positive showing sign of fever and respiratory issues ^{8,9}. The study suggests that thorough epidemiological investigations in combination with multiple detection methods (e.g., RT-PCR, chest CT, Rapid IgM-IgG, and serum CRP level) can identify the asymptomatic carriers ^{10,11} in the community among varying clinical manifestations between individuals. Another study supports the possibility of asymptomatic transmission among familial-cluster during the incubation period ¹². In a familial-cluster of 5 positive COVID-19 patients had contact with other asymptomatic family members who returned from the Wuhan, suggestive of asymptomatic transmission ⁷.

Studies included in the current meta-analysis were checked for the likelihood ratio (LR) between random effect and fixed-effect models for the distribution of asymptomatic COVID-19 transmission among the community.

Among pregnant woman's fetuses are at high-risk during any disease outbreak, in pregnant woman with asymptomatic COVID-19 viral infection delivered a baby negative for the COVID-19 nucleic acid test Suggestive of no vertical transmission among neonates born to COVID-19 infected mothers $^{14,42-49}$. In Wuhan, a lower fatality rate and higher discharge rate were observed than in Beijing. It is crucial to identify and take necessary control measures among adults of asymptomatic cases to prevent transmission 21 . In South Korea, 41 asymptomatic adults were identified and were confirmed by RT-PCR out of 213 cases 17 . Among 100 asymptomatic cases, 60% developed delayed symptoms, and none of the asymptomatic cases died, suggesting asymptomatic transmission during the incubation period 18 . Another study did not observe any difference in the symptomatic and asymptomatic COVID-19 individuals has advantages in highly suspicious cases with negative nucleic acid testing 17 . In adults, a serological investigation among 31 out of 34 cases with asymptomatic infection did not require oxygen support during hospitalization 15 . Theoretically, the quantified infection transmission rate shows the estimated risk ratio (RR) of infectivity [3.9%, (95%CI: 1.5 – 11.8)] of symptomatic against asymptomatic.

In asymptomatic adults, the transmission was significantly smaller than that of the symptomatic cases ¹⁶. No gender difference among males and females was observed for asymptomatic transmission ²⁰.

Further longitudinal surveillance via virus nucleic acid testing is warranted to identify and control the viral load among asymptomatic CVOID-19 cases ²⁴ in adults. In a study, 4 asymptomatic cases were quarantined for 14 days, and none was able to transmit the infections due to managing proper isolation and quarantine of the cases ¹⁹.

Asymptomatic COVID-19 transmission was seen in children ²⁶. In a study, 24 asymptomatic cases were screened from close contacts of asymptomatic COIVD-19 ²⁵. Another study supports the multiple site sampling of close contacts should be performed ¹ among children. In a review, it was observed that the adults as compared to children with COVID-19 infection show mild clinical symptoms and radiological manifestations as previously reported for SARS- and the Middle East respiratory syndrome (MERS)-CoV ⁵⁰.

Health care workers in a nursing facility: Rapid transmission of COVID-19 had been reported in 76 residents cases. and 23 (30.3%) had positive test results, and approximately 13 were asymptomatic on the day of testing, suggesting the possibility of asymptomatic transmission of COVID-19 ²⁷. Establishing effective infection control strategies to prevent the transmission among frontline health care workers and patients from COVID-19 infections should be managed urgently and on priority. In another study, out of 48 participants observed, two asymptomatic cases become positive, suggesting appropriate symptom-based testing strategies are essential to prevent outbreaks of COVID-19 within hospital settings ²⁹. In the USA, health care workers not wearing respirators were exposed to an asymptomatic CVOID-19 patient without developing clinical illness ²⁸.

Traveler: In Korea, COVID-19 was transmitted by 16 infected travelers from other countries. The disease was infectious at this stage, which resulted from close contacts of asymptomatic carriers ³⁰. Most of the infections on board the Diamond Princess Cruise ship highlight the asymptomatic transmission of COVID-19 in confined settings. To further mitigate the transmissibility of COVID-19, it may be advised to minimize the number of gathering in confined settings ³². A 36-year-old traveler returned from Wuhan was found COVID-19 positive,

and other health workers who were in close contact with the patients were also tested RT-PCR positive. However, the patient initially had no symptoms ³³. A higher proportion of asymptomatic (12%) was reported among travelers returning to Brunei. In another study, it was suggested to increase the testing facility for asymptomatic COVID-19 cases ³⁴. Similarly, an asymptomatic COVID-19 patient showed viral transmissibility without showing any signs and symptoms in travelers from China ³¹. Although, we recommend early isolation for and social distancing for asymptomatic COVID-19 cases, which may led to psychological and emotional loss as reported in qualitative study from UK⁵¹.

Limitations: There are some limitations in the current systematic review and meta-analysis. A mixed population, a continuous variable, variation in clinical conditions, and statistical methods may differ and cause heterogeneity among studies included in the current meta-analysis. Further, the study included only asymptomatic COVID-19 transmission reported cases that were included.

Study Importance: This is the first study reviewing the possibility of asymptomatic COVID-19 transmission at different levels in the community and identified the potential role of isolation, identification of close contacts, social distancing and testing asymptomatic COVID-19 cases with chest CT scan and nucleic acid testing to minimize the spread of the virus in the community.

The implication of our study: This is the first meta-analysis on the possibility of asymptomatic COVID-19 transmission covering different levels in the community.

Conclusion: Currently, there is no evidence of COVID-19 transmission ability in the asymptomatic stage, but evidence suggests that asymptomatic infections were not limited from neonates to children and adults. In young people, strong immune status was supposed to be protected against the COVID-19 severity. We hypothesize that the asymptomatic carriers, either children or adults, should be vigilant as they are capable of shielding and transmitting the infection in their incubation period without showing any signs and symptoms. As the evidence supports the involvement of lung function in asymptomatic COVID-19 cases, we recommend the chest CT scans among asymptomatic cases, a useful tool to monitor and trace cases in their incubation period.

Contributors: Dr. Khaiwal Ravindra: Concept design, data extraction, interpretation, final correction and writing first draft. Mr. Vivek Singh Malik: Data extraction, interpretation and writing first draft. Dr. Bijaya K Padhi: Interpretation, internal review of data, review and editing. Dr. Sonu Goel: Discussion, review and editing. Dr. Madhu Gupta: Internal review of data, review and editing.

Acknowledgment: We thank the Department of Community Medicine and School of Public Health, PGIMER, and Indian Council of Medical Research, New Delhi.

Funding/Support: None.

Conflict of Interest: None.

Pateint consent: not required.

Data sharing statement: No addditonal data avialable.

References:

- 1. Tan X, Huang J, Zhao F, Zhou Y, Li J-Q, Wang X-Y. [Clinical features of children with SARS-CoV-2 infection: an analysis of 13 cases from Changsha, China]. *Zhongguo Dang Dai Er Ke Za Zhi Chin J Contemp Pediatr.* 2020;22(4):294-298.
- 2. Chen T-M, Rui J, Wang Q-P, Zhao Z-Y, Cui J-A, Yin L. A mathematical model for simulating the phase-based transmissibility of a novel coronavirus. *Infect Dis Poverty*. 2020;9(1):24. doi:10.1186/s40249-020-00640-3
- 3. Rahimi F, Talebi Bezmin Abadi A. Challenges of managing the asymptomatic carriers of SARS-CoV-2. *Travel Med Infect Dis.* Published online April 2020:101677. doi:10.1016/j.tmaid.2020.101677
- 4. He G, Sun W, Fang P, et al. The clinical feature of silent infections of novel coronavirus infection (COVID-19) in Wenzhou. *J Med Virol*. Published online April 10, 2020. doi:10.1002/jmv.25861
- 5. Wang Y, Kang H, Liu X, Tong Z. Asymptomatic cases with SARS-CoV-2 infection. *J Med Virol*. Published online May 22, 2020:jmv.25990. doi:10.1002/jmv.25990
- 6. Park SW, Cornforth DM, Dushoff J, Weitz JS. The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak. *Epidemics*. 2020;31:100392. doi:10.1016/j.epidem.2020.100392
- 7. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*. 2020;323(14):1406. doi:10.1001/jama.2020.2565

- 8. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet*. 2020;395(10223):514-523. doi:10.1016/S0140-6736(20)30154-9
- 9. Chen M, Fan P, Liu Z, et al. A SARS-CoV-2 familial cluster infection reveals asymptomatic transmission to children. *J Infect Public Health*. 2020;13(6):883-886. doi:10.1016/j.jiph.2020.05.018
- Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients. *J Med Virol*. Published online March 19, 2020. doi:10.1002/jmv.25776
- 11. Qian G, Yang N, Ma AHY, et al. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China. *Clin Infect Dis.* Published online March 23, 2020:ciaa316. doi:10.1093/cid/ciaa316
- 12. Ye F, Xu S, Rong Z, et al. Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. *Int J Infect Dis.* 2020;94:133-138. doi:10.1016/j.ijid.2020.03.042
- 13. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. *Transfus Med Rev.* 2020;34(2):75-80. doi:10.1016/j.tmrv.2020.02.003
- 14. Lu D, Sang L, Du S, Li T, Chang Y, Yang X. Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission. *J Med Virol*. Published online April 30, 2020:jmv.25927. doi:10.1002/jmv.25927
- 15. Al Hosani FI, Kim L, Khudhair A, et al. Serologic Follow-up of Middle East Respiratory Syndrome Coronavirus Cases and Contacts—Abu Dhabi, United Arab Emirates. *Clin Infect Dis.* 2019;68(3):409-418. doi:10.1093/cid/ciy503
- 16. He D, Zhao S, Lin Q, et al. The relative transmissibility of asymptomatic COVID-19 infections among close contacts. *Int J Infect Dis.* 2020;94:145-147. doi:10.1016/j.ijid.2020.04.034
- 17. Kim G -u., Kim M-J, Ra SH, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. *Clin Microbiol Infect*. Published online May 2020:S1198743X20302688. doi:10.1016/j.cmi.2020.04.040
- 18. Kong W, Wang Y, Hu J, Chughtai A, Pu H. Comparison of clinical and epidemiological characteristics of asymptomatic and symptomatic SARS-CoV-2 infection: A multi-center study in Sichuan Province, China. *Travel Med Infect Dis.* Published online May 2020:101754. doi:10.1016/j.tmaid.2020.101754
- 19. Park SY, Kim Y-M, Yi S, et al. Coronavirus Disease Outbreak in Call Center, South Korea. *Emerg Infect Dis.* 2020;26(8). doi:10.3201/eid2608.201274

- 20. Qiu C, Deng Z, Xiao Q, et al. Transmission and clinical characteristics of coronavirus disease 2019 in 104 outside-Wuhan patients, China. *J Med Virol*. Published online May 5, 2020:jmv.25975. doi:10.1002/jmv.25975
- 21. Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80(4):401-406. doi:10.1016/j.jinf.2020.02.018
- 22. Yin G, Jin H. Comparison of Transmissibility of Coronavirus Between Symptomatic and Asymptomatic Patients: Reanalysis of the Ningbo COVID-19 Data. *JMIR Public Health Surveill*. 2020;6(2):e19464. doi:10.2196/19464
- 23. Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. SARS-CoV-2 and COVID-19: The most important research questions. *Cell Biosci.* 2020;10(1):40. doi:10.1186/s13578-020-00404-4
- 24. Zhou R, Li F, Chen F, et al. Viral dynamics in asymptomatic patients with COVID-19. *Int J Infect Dis.* 2020;96:288-290. doi:10.1016/j.ijid.2020.05.030
- 25. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci*. 2020;63(5):706-711. doi:10.1007/s11427-020-1661-4
- 26. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *Lancet Infect Dis.* 2020;20(6):689-696. doi:10.1016/S1473-3099(20)30198-5
- 27. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(13):377-381. doi:10.15585/mmwr.mm6913e1
- 28. Lucar J, Navalkele B, Becker BP, Reed CD, Parham J. Healthcare Personnel Exposure to a Patient with Asymptomatic SARS-CoV2 Infection during a Prolonged Surgical Intervention. *Am J Infect Control*. Published online June 2020:S0196655320303527. doi:10.1016/j.ajic.2020.05.036
- 29. Schwierzeck V, König JC, Kühn J, et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. *Clin Infect Dis.* Published online April 27, 2020:ciaa491. doi:10.1093/cid/ciaa491
- COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea. Osong Public Health Res Perspect. 2020;11(1):8-14. doi:10.24171/j.phrp.2020.11.1.03
- 31. Hu X, Gao J, Luo X, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease

2019 (COVID-19) Pneumonia. *Obstet Gynecol.* 2020;Publish Ahead of Print. doi:10.1097/AOG.00000000003926

- Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance*. 2020;25(10). doi:10.2807/1560-7917.ES.2020.25.10.2000180
- 33. Wan R, Mao Z-Q, He L-Y, Hu Y-C, Wei-Chen. Evidence from two cases of asymptomatic infection with SARS-CoV-2: Are 14 days of isolation sufficient? *Int J Infect Dis*. 2020;95:174-175. doi:10.1016/j.ijid.2020.03.041
- 34. Wong J, Abdul Aziz ABZ, Chaw L, et al. High proportion of asymptomatic and presymptomatic COVID-19 infections in air passengers to Brunei. *J Travel Med*. Published online May 5, 2020:taaa066. doi:10.1093/jtm/taaa066
- 35. Malik VS, Ravindra K, Attri SV, Bhadada SK, Singh M. Higher Body Mass Index Is an Important Risk Factor in COVID-19 Patients: A Systematic Review. *SSRN Electron J*. Published online 2020. doi:10.2139/ssrn.3605087
- 36. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
- 37. Nuorti JP, Butler JC, Farley MM, et al. Cigarette Smoking and Invasive Pneumococcal Disease. *N Engl J Med.* 2000;342(10):681-689. doi:10.1056/NEJM200003093421002
- 38. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. *BMJ*. 2006;333(7568):597-600. doi:10.1136/bmj.333.7568.597
- 39. Krüger K, Mooren F-C, Pilat C. The Immunomodulatory Effects of Physical Activity. *Curr Pharm Des.* 2016;22(24):3730-3748. doi:10.2174/1381612822666160322145107
- 40. Lasselin J, Alvarez-Salas E, Grigoleit J-S. Well-being and immune response: a multisystem perspective. *Curr Opin Pharmacol*. 2016;29:34-41. doi:10.1016/j.coph.2016.05.003
- 41. Pearson-Stuttard J, Blundell S, Harris T, Cook DG, Critchley J. Diabetes and infection: assessing the association with glycaemic control in population-based studies. *Lancet Diabetes Endocrinol.* 2016;4(2):148-158. doi:10.1016/S2213-8587(15)00379-4
- Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet*. 2020;395(10226):809-815. doi:10.1016/S0140-6736(20)30360-3
- 43. Chen S, Huang B, Luo DJ, et al. [Pregnancy with new coronavirus infection: clinical characteristics and placental pathological analysis of three cases]. *Zhonghua Bing Li Xue Za Zhi*. 2020;49(5):418-423. doi:10.3760/cma.j.cn112151-20200225-00138

- 44. Chen Y, Peng H, Wang L, et al. Infants Born to Mothers With a New Coronavirus (COVID-19). *Front Pediatr*. 2020;8:104. doi:10.3389/fped.2020.00104
- 45. Dashraath P, Wong JLJ, Lim MXK, et al. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. *Am J Obstet Gynecol.* 2020;222(6):521-531. doi:10.1016/j.ajog.2020.03.021
- 46. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. *J Infect*. Published online March 2020:S0163445320301092. doi:10.1016/j.jinf.2020.02.028
- 47. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med.* 2020;26(4):502-505. doi:10.1038/s41591-020-0817-4
- 48. Zhang L, Jiang Y, Wei M, et al. [Analysis of the pregnancy outcomes in pregnant women with COVID-19 in Hubei Province]. *Zhonghua Fu Chan Ke Za Zhi*. 2020;55(3):166-171. doi:10.3760/cma.j.cn112141-20200218-00111
- 49. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019nCoV pneumonia. *Transl Pediatr*. 2020;9(1):51-60. doi:10.21037/tp.2020.02.06
- 50. Zimmermann P, Curtis N. COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features. *Pediatr Infect Dis J.* 2020;39(6):469-477. doi:10.1097/INF.00000000002700
- Williams SN, Armitage CJ, Tampe T, et al. Public perceptions and experiences of social distancing and social isolation during the COVID-19 pandemic: a UK-based focus group study. BMJ Open 2020;10:e039334. doi:10.1136/bmjopen-2020-039334




Figure 1: PRISMA Chart





Figure 2: Forest plot asymptomatic positivity of COVID-19 among population

Feng Ye (2020) Guoaing Qian (2020) Jasper Fuk-woochan (2020) Ming chen (2020) Shubia Lu (2020) Yan Bai (2020) Subtotal (l^2 = 46.0%, p = 0.10) Adults Chengfeng Qiu (2020) Daihie He (2020) Farida Ismail Al Hosani (2020) Guosheng Yin (2020) Guosheng Yin (2020) Shin Young Park (2020) Shin Young Park (2020) Subtotal (l^2 = 98.4%, p = 0.00) Children Haiyan Qiu (2020) Subtotal (l^2 = 98.4%, p = 0.00) Children Haiyan Qiu (2020) Subtotal (l^2 = 98.4%, p = 0.00) Children Haiyan Qiu (2020) Subtotal (l^2 = 9.6, p = .) Health Care Worker Anne Kimball (2020) Subtotal (l^2 = .%, p = .)	Study		ES (95% CI)	% Weight
Feng Ye (2020) Guoaing Qian (2020) Jasper Fuk-woochan (2020) Ming chen (2020) Yan Bai (2020) Yan Bai (2020) Subtotal ($P2 = 46.0\%$, p = 0.10) Adults Chengfeng Qiu (2020) Daihie He (2020) Earida Ismail AI Hosani (2020) Guosheng Yin (2020) Bubtotal ($P2 = 46.0\%$, p = 0.10) Adults Chengfeng Qiu (2020) Baihie He (2020) Earida Ismail AI Hosani (2020) Guosheng Yin (2020) Bubtotal ($P2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($P2 = 98.4\%$, p = .) Children Haiyan Qiu (2020) Subtotal ($P2 = 98.2\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($P2 = 98.2\%$, p = 0.00) Tri Quynh Mai Le (2020) Subtotal ($P2 = 97.28\%$, p = 0.00) Subtotal ($P2 = 97.28\%$, p = 0.00) Children Heterogeneity between groups: p = 0.5.8 Overall ($P2 = 97.28\%$, p = 0.00) Subtotal ($P2 = 97.28\%$, p =	Familial Cluster	i		
Guoänig Qian (2020) Jasper Fuk-wochan (2020) Ming chen (2020) Subtotal ($^{12} = 46.0\%$, p = 0.10) Adults Chengfeng Qiu (2020) Daihie He (2020) Gu. Kim (2020) Guisenerg Yin (2020) Heng Meng (2020) Rvi Zhou (2020) Subtotal ($^{12} = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($^{12} = .\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($^{12} = .\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($^{12} = .\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($^{12} = .\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($^{12} = .\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($^{12} = .\%$, p = .) Subtotal			0.40 (0.05, 0.85)	2.90
Jasper ⁷ uk-wochan (2020) Ming chen (2020) Subtotal ($^{1}2 = 46.0\%, p = 0.10$) Adults Chengfeng Glu (2020) Daihie He (2020) Daihie He (2020) Daihie He (2020) Daihie He (2020) Causkine (2020) Guosheng Yin (2020) Guosheng Yin (2020) Heng Meng (2020) Subtotal ($^{1}2 = 98.4\%, p = 0.00$) Subtotal ($^{1}2 = 98.4\%, p = 0.00$) Children Haiyan Olu (2020) Subtotal ($^{1}2 = .\%, p = .$) Health Care Worker Anne Kimball (2020) Subtotal ($^{1}2 = .\%, p = .$) Health Care Worker Anne Kimball (2020) Subtotal ($^{1}2 = .\%, p = .$) Traveler COVID-19 Team (2020) Vera Schoierzeck (2020) Subtotal ($^{1}2 = .\%, p = .$) Traveler COVID-19 Team (2020) Subtotal ($^{1}2 = .\%, p = .$) Traveler COVID-19 Team (2020) Subtotal ($^{1}2 = .\%, p = .$) Traveler COVID-19 Team (2020) Subtotal ($^{1}2 = .\%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenij Mizumoto (2020) Kenij Mizumoto (2020) Subtotal ($^{1}2 = .\%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenij Mizumoto (2020) K				
Ming chen (2020) Shubia Lu (2020) Shubia Lu (2020) Subtotal ($l^2 = 46.0\%$, p = 0.10) Adults Chengleng Giu (2020) Daihie He (2020) Farida Ismail Al Hosani (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Traveler COVID-19 Team (2020) Subtotal ($l^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Subtotal ($l^2 = 98.2\%$, p = 0.00) Heterogeneity between groups: p = 0.5.8 Overall ($l^2 = 97.28\%$, p = 0.00);				3.05
Yan Bai (2020) Subtotal ($l^{12} = 46.0\%$, p = 0.10) Adults Chengfeng Qiu (2020) Daihie He (2020) Farida Ismail Al Hosani (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) Subtotal ($l^{12} = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($l^{12} = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($l^{12} = 98.4\%$, p = 0.00) Traveler COVID-19 Team (2020) Subtotal ($l^{12} = 96.2\%$, p = 0.00) Traveler COVID-19 Team (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Traveler COVID-19 Team (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Traveler COVID-19 Team (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Worker Anne Kimbal (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00); Health Care Wor	Ming chen (2020)			2.44
Subtotal $(h^2 = 46.0\%, p = 0.10)$ Adults Chengfeng Qiu (2020) Daihie He (2020) Gu, Kim (2020) Gu, Kim (2020) Gu, Kim (2020) Guosheng Yin (2020) Rui Zhou (2020) Shin Young Park (2020) Shin Young Park (2020) Sigia Tian (2020) Wei Fang Kong (2020) Subtotal (h^2 = 98.4\%, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal (h^2 = 98.4\%, p = .) Health Care Worker Anne Kimbal (2020) Vera Schoierzeck (2020) Subtotal (h^2 = 98.2\%, p = .) Traveler COVID-19 Team (2020) Xenji Mizumoto (2020) Kenji Mizu	Shubia Lu (2020)			2.44
Adults Chargerg Qiu (2020) Daihie He (2020) Farida Ismail Al Hosani (2020) Gu Skim (2020) Guosheng Yin (2020) Guosheng Yin (2020) Rui Zhou (2020) Shin Young Park (2020) Shin Young Park (2020) Subtotal ($l^{12} = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($l^{12} = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($l^{12} = -\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($l^{12} = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($l^{12} = 98.2\%$, p = 0.00) Heterogeneity between groups: p = 0.5-8 Overall ($l^{12} = 97.28\%$, p = 0.00);	Yan Bai (2020)		0.17 (0.00, 0.64)	3.05
Chengfeng Qiu (2020) Daihie He (2020) Farida Ismail Al Hosani (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) Rui Zhou (2020) Nin Young Park (2020) Shin Young Park (2020) Subtotal ($h^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($h^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Subtotal ($h^2 = -\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Keni Mizumoto (2020) Keni Mizumoto (2020) Keni Wang (2020) Keni Mizumoto (2020) Ke	Subtotal $(I^2 = 46.0\%, p = 0.10)$	$\langle \rangle$	0.32 (0.09, 0.59)	17.15
Daihie He (2020) Farida Ismail Al Hosani (2020) Gu. Kim (2020) Guosheng Yin (2020) Rui Zhou (2020) Rui Zhou (2020) Sijia Tian (2020) Sijia Tian (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal ($l^2 = .\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($l^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($l^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($l^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($l^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Subtotal ($l^2 = .\%$, p = 0.00) Heterogeneity between groups: p = 0.578 Overall ($l^2 = 97.28\%$, p = 0.00);	Adults			
Farida Ismail Al Hosani (2020) G.u. Kim (2020) G.u. Kim (2020) G.u. Kim (2020) Heng Meng (2020) Rui Zhou (2020) Shin Young Park (2020) Shin Young Park (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Children Haiyan Qiu (2020) Xin Tan (2020) Children Haiyan Qiu (2020) Subtotal ($l^2 = -\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($l^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Subtotal ($l^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2	Chengfeng Qiu (2020)		0.05 (0.02, 0.11)	4.20
G.u. Kim (2020) Guosheng Yin (2020) Heng Meng (2020) Rui Zhou (2020) Shin Young Park (2020) Shin Young Park (2020) Subtotal ($h^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Subtotal ($h^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Subtotal ($h^2 = -\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Subtotal ($h^2 = -\%$, p = .) Traveler COVID-19 Team (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Heterogeneity between groups: p = 0.5.8 Overall ($h^2 = 97.28\%$, p = 0.00);	Daihie He (2020)		0.16 (0.11, 0.22)	
Guosheng Yin (2020) Heng Meng (2020) Rui Zhou (2020) Shin Young Park (2020) Sijia Tian (2020) Subtotal ($P2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal ($P2 = 98.4\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($P2 = .\%$, p = .) Health Care Worker Anne Kimball (2020) Subtotal ($P2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Subtotal ($P2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Subtotal ($P2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Kenji Mizum	Farida Ismail Al Hosani (2020)	_ ·	0.91 (0.76, 0.98)	
Heng Meng (2020) Rui Zhou (2020) Shin Young Park (2020) Shin Young Park (2020) Subtotal ($l^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal ($l^2 = .\%$, p = .) Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal ($l^2 = 98.2\%$, p = 0.00) Heterogeneity between groups: p = 0.5-8 Overall ($l^2 = 97.28\%$, p = 0.00);	G.u. Kim (2020)		0.19 (0.14, 0.25)	4.25
Rui Žhou (2020) Shin Young Park (2020) Shin Young Park (2020) Sijia Tian (2020) Wei Fang Kong (2020) Subtotal ($h^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Zhiliang Hu (2020) Zhiliang Hu (2020) Zhiliang Hu (2020) Subtotal ($h^2 = .\%$, p = .) Health Care Worker Anne Kimball (2020) Vera Schoierzeck (2020) Subtotal ($h^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Subtotal ($h^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Subtotal ($h^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Subtotal ($h^2 = .\%$, p = .0.00) Heterogeneity between groups: p = 0.578 Overall ($h^2 = 97.28\%$, p = 0.00);	Guosheng Yin (2020)		0.16 (0.11, 0.22)	4.24
Shin Young Park (2020) Sija Tian (2020) Wei Fang Kong (2020) Subtotal ($h^2 = 98.4\%$, $p = 0.00$) Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal ($h^2 = .\%$, $p = .$) Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($h^2 = .\%$, $p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Thi Quynh Mai Le (2020) Subtotal ($h^2 = 98.2\%$, $p = 0.00$) Heterogeneity between groups: $p = 0.538$ Overall ($h^2 = 97.28\%$, $p = 0.00$); 0.04 (0.01, 0.10) 4.19 0.04 (0.01, 0.10) 4.28 0.03 (0.01, 0.02) 4.28 0.28 (0.14, 0.45) 4.01 0.15 (0.02, 0.45) 3.59 0.29 (0.13, 0.51) 3.88 0.26 (0.16, 0.37) 11.48 0.26 (0.16, 0.37) 11.48 0.17 (0.09, 0.27) 4.16 1.00 (0.03, 1.00) 1.55 0.04 (0.01, 0.14) 4.08 0.06 (0.00, 0.31) 9.79 0.11 (0.76, 0.98) 3.99 0.12 (0.07, 0.18) 4.22 0.51 (0.47, 0.55) 4.28 0.031 (0.19, 0.44) 100.00	Heng Meng (2020)		1.00 (0.94, 1.00)	4.12
Sijia Tian (2020) Wei Fang Kong (2020) Subtotal ($h^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Zin Tan (2020) Subtotal ($h^2 = 98.4\%$, p = 0.00) Children Haiyan Qiu (2020) Xin Tan (2020) Subtotal ($h^2 = -\%$, p = .) Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($h^2 = .\%$, p = .) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Subtotal ($h^2 = 98.2\%$, p = 0.00) Heterogeneity between groups: p = 0.5:8 Overall ($h^2 = 97.28\%$, p = 0.00); Heterogeneity between groups: p = 0.5:8 Overall ($h^2 = 97.28\%$, p = 0.00);	Rui Zhou (2020)	_	1.00 (0.89, 1.00)	3.97
Wei Fang Kong (2020) 0.20 (0.16, 0.23) 4.28 Subtotal ($l^2 = 98.4\%$, $p = 0.00$) 0.37 (0.19, 0.57) 41.74 Children 0.28 (0.14, 0.45) 4.01 Haiyan Qiu (2020) 0.15 (0.02, 0.45) 3.59 Zhiliang Hu (2020) 0.26 (0.16, 0.37) 11.48 Health Care Worker 0.26 (0.16, 0.37) 11.48 Health Care Worker 0.17 (0.09, 0.27) 4.16 Anne Kimball (2020) 0.37 (0.19, 0.57) 4.16 Jose Lucar (2020) 0.17 (0.09, 0.27) 4.16 Vera Schoierzeck (2020) 0.04 (0.01, 0.14) 4.08 Subtotal ($l^{h}2 = .\%$, $p = .$) 0.91 (0.76, 0.98) 3.99 Traveler 0.91 (0.76, 0.98) 3.99 COVID-19 Team (2020) 0.51 (0.47, 0.55) 4.28 Kenji Mizumoto (2020) 0.31 (0.00, 0.09) 4.16 Kenji Waizumoto (2020) 0.31 (0.19, 0.44) 100.00 Butotal ($l^{h}2 = 97.28\%$, $p = 0.00$); 0.31 (0.19, 0.44) 100.00	Shin Young Park (2020)		0.04 (0.01, 0.10)	4.19
Subtotal $(l^{2} = 98.4\%, p = 0.00)$ Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal $(l^{2} = .\%, p = .)$ Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal $(l^{2} = .\%, p = .)$ Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Kenji Mizumoto (2020) Ren Wan (2020) Subtotal $(l^{2} = 98.2\%, p = 0.00)$ Heterogeneity between groups: p = 0.558 Overall $(l^{2} = 97.28\%, p = 0.00)$; dut = 0.00 dut =	Sijia Tian (2020)	 •	0.05 (0.03, 0.08)	4.26
Children Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal ($l^2 = .\%, p = .$) Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^2 = .\%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal ($l^2 = 98.2\%, p = 0.00$); Heterogeneity between groups: p = 0.5:8	Wei Fang Kong (2020)		0.20 (0.16, 0.23)	
Haiyan Qiu (2020) Xin Tan (2020) Zhiliang Hu (2020) Subtotal ($l^{2}2 = .%, p = .$) Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^{2}2 = .%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal ($l^{2}2 = 98.2\%, p = 0.00$) Heterogeneity between groups: p = 0.5.8 Overall ($l^{2}2 = 97.28\%, p = 0.00$);	Subtotal (I ² = 98.4%, p = 0.00)	>	0.37 (0.19, 0.57)	41.74
Xin Tan (2020) Zhiliang Hu (2020) Subtotal ($l^{1/2} = .%, p = .$) Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^{1/2} = .%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal ($l^{1/2} = 98.2\%, p = 0.00$) Heterogeneity between groups: $p = 0.5.8$ Overall ($l^{1/2} = 97.28\%, p = 0.00$); 0.15 (0.02, 0.45) 3.59 0.29 (0.13, 0.51) 3.88 0.26 (0.16, 0.37) 11.48 0.17 (0.09, 0.27) 4.16 1.00 (0.03, 1.00) 1.55 0.04 (0.01, 0.14) 4.08 0.06 (0.00, 0.31) 9.79 0.91 (0.76, 0.98) 3.99 0.12 (0.07, 0.18) 4.22 0.51 (0.47, 0.55) 4.28 0.03 (0.00, 0.09) 4.16 0.14 (0.00, 0.58) 3.17 0.32 (0.06, 0.65) 19.84 0.31 (0.19, 0.44) 100.00	Children			
Zhiliang Hu (2020) Subtotal ($l^{2}2 = .\%, p = .$) Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^{2}2 = .\%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Subtotal ($l^{2}2 = 98.2\%, p = 0.00$); Heterogeneity between groups: p = 0.538 Overall ($l^{2}2 = 97.28\%, p = 0.00$); D.29 (0.13, 0.51) 3.88 0.26 (0.16, 0.37) 11.48 0.17 (0.09, 0.27) 4.16 1.00 (0.03, 1.00) 1.55 0.04 (0.01, 0.14) 4.08 0.04 (0.01, 0.14) 4.08 0.06 (0.00, 0.31) 9.79 0.91 (0.76, 0.98) 3.99 0.12 (0.07, 0.18) 4.22 0.51 (0.47, 0.55) 4.28 0.03 (0.00, 0.09) 4.16 0.14 (0.00, 0.58) 3.17 0.32 (0.06, 0.65) 19.84 0.31 (0.19, 0.44) 100.00				
Subtotal $(l^{h2} = .\%, p = .)$ Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal $(l^{h2} = .\%, p = .)$ Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Subtotal $(l^{h2} = 98.2\%, p = 0.00)$ Heterogeneity between groups: p = 0.55 Overall $(l^{h2} = 97.28\%, p = 0.00)$; 0.26 (0.16, 0.37) 11.48 0.17 (0.09, 0.27) 4.16 1.00 (0.03, 1.00) 1.55 0.04 (0.01, 0.14) 4.08 0.06 (0.00, 0.31) 9.79 0.91 (0.76, 0.98) 3.99 0.12 (0.07, 0.18) 4.22 0.51 (0.47, 0.55) 4.28 0.03 (0.00, 0.09) 4.16 0.14 (0.00, 0.58) 3.17 0.32 (0.06, 0.65) 19.84 0.31 (0.19, 0.44) 100.00	. ,			
Health Care Worker Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^{1/2} = .%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal ($l^{1/2} = 98.2\%, p = 0.00$) Heterogeneity between groups: p = 0.5.8 Overall ($l^{1/2} = 97.28\%, p = 0.00$);				
Anne Kimball (2020) Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^2 =, p =$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal ($l^2 = 98.2\%, p = 0.00$) Heterogeneity between groups: p = 0.5.8 Overall ($l^2 = 97.28\%, p = 0.00$); 0.17 (0.09, 0.27) 4.16 1.00 (0.03, 1.00) 1.55 0.04 (0.01, 0.14) 4.08 0.06 (0.00, 0.31) 9.79 0.91 (0.76, 0.98) 3.99 0.12 (0.07, 0.18) 4.22 0.51 (0.47, 0.55) 4.28 0.03 (0.00, 0.09) 4.16 0.14 (0.00, 0.58) 3.17 0.32 (0.06, 0.65) 19.84 0.31 (0.19, 0.44) 100.00	Subtotal $(I^2 = .\%, p = .)$	\mathbf{Q}	0.26 (0.16, 0.37)	11.48
Jose Lucar (2020) Vera Schoierzeck (2020) Subtotal ($l^{1/2} = .\%, p = .$) Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal ($l^{1/2} = 98.2\%, p = 0.00$) Heterogeneity between groups: p = 0.538 Overall ($l^{1/2} = 97.28\%, p = 0.00$);	Health Care Worker	_		
Vera Schoierzeck (2020) $0.04 (0.01, 0.14)$ 4.08 Subtotal (I/2 = .%, p = .) $0.06 (0.00, 0.31)$ 9.79 Traveler $0.91 (0.76, 0.98)$ 3.99 COVID-19 Team (2020) $0.12 (0.07, 0.18)$ 4.22 Justin WONG (2020) $0.12 (0.07, 0.18)$ 4.22 Kenji Mizumoto (2020) $0.51 (0.47, 0.55)$ 4.28 Ren Wan (2020) $0.33 (0.00, 0.09)$ 4.16 Thi Quynh Mai Le (2020) $0.31 (0.00, 0.58)$ 3.17 Subtotal (I/2 = 98.2%, p = 0.00) $0.31 (0.19, 0.44)$ 100.00				
Subtotal $(I^{A2} = .\%, p = .)$ Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Thi Quynh Mai Le (2020) Subtotal $(I^{A2} = 98.2\%, p = 0.00)$ Heterogeneity between groups: p = 0.538 Overall $(I^{A2} = 97.28\%, p = 0.00)$; 0.06(0.00, 0.31) 9.79 0.91(0.76, 0.98) 3.99 0.12(0.07, 0.18) 4.22 0.51(0.47, 0.55) 4.28 0.03(0.00, 0.09) 4.16 0.14(0.00, 0.58) 3.17 0.32(0.06, 0.65) 19.84 0.31(0.19, 0.44) 100.00				
Traveler COVID-19 Team (2020) Justin WONG (2020) Kenji Mizumoto (2020) Ren Wan (2020) Subtotal ($l^2 = 98.2\%$, p = 0.00) Heterogeneity between groups: p = 0.538 Overall ($l^2 = 97.28\%$, p = 0.00);				
COVID-19 Team (2020) \bullet 0.91 (0.76, 0.98) 3.99 Justin WONG (2020) \bullet 0.91 (0.76, 0.98) 3.99 Kenji Mizumoto (2020) \bullet 0.12 (0.07, 0.18) 4.22 Ren Wan (2020) $0.51 (0.47, 0.55)$ 4.28 Thi Quynh Mai Le (2020) $0.31 (0.00, 0.09)$ 4.16 Subtotal (I^2 = 98.2%, p = 0.00) $0.32 (0.06, 0.65)$ 19.84 Heterogeneity between groups: p = 0.538 $0.31 (0.19, 0.44)$ 100.00	Subtotal $(I^2 = .\%, p = .)$		0.06 (0.00, 0.31)	9.79
Justin WONG (2020) 0.12 (0.07, 0.18) 4.22 Kenji Mizumoto (2020) 0.51 (0.47, 0.55) 4.28 Ren Wan (2020) 0.31 (0.00, 0.09) 4.16 Thi Quynh Mai Le (2020) 0.14 (0.00, 0.58) 3.17 Subtotal (I^2 = 98.2%, p = 0.00) 0.32 (0.06, 0.65) 19.84 Heterogeneity between groups: p = 0.538 0.31 (0.19, 0.44) 100.00				0.05
Kenji Mizumoto (2020) 0.51 (0.47, 0.55) 4.28 Ren Wan (2020) 0.31 (0.00, 0.09) 4.16 Thi Quynh Mai Le (2020) 0.14 (0.00, 0.58) 3.17 Subtotal (I^2 = 98.2%, p = 0.00) 0.32 (0.06, 0.65) 19.84 Heterogeneity between groups: p = 0.538 0.31 (0.19, 0.44) 100.00	. ,			
Ren Wan (2020) 0.03 (0.00, 0.09) 4.16 Thi Quynh Mai Le (2020) 0.14 (0.00, 0.58) 3.17 Subtotal (I^2 = 98.2%, p = 0.00) 0.32 (0.06, 0.65) 19.84 Heterogeneity between groups: p = 0.538 0.31 (0.19, 0.44) 100.00	. ,			
Thi Quynh Mai Le (2020) 0.14 (0.00, 0.58) 3.17 Subtotal (I/2 = 98.2%, p = 0.00) 0.32 (0.06, 0.65) 19.84 Heterogeneity between groups: p = 0.538 0.31 (0.19, 0.44) 100.00 Overall (I/2 = 97.28%, p = 0.00); 0.31 (0.19, 0.44) 100.00		. ! 🗖		-
Subtotal (I/2 = 98.2%, p = 0.00) 0.32 (0.06, 0.65) 19.84 Heterogeneity between groups: p = 0.538 0.31 (0.19, 0.44) 100.00 Overall (I/2 = 97.28%, p = 0.00); 0.31 (0.19, 0.44) 100.00				
Heterogeneity between groups: p = 0.538 Overall (l^2 = 97.28%, p = 0.00); 0.31 (0.19, 0.44) 100.00				
Overall (l^2 = 97.28%, p = 0.00);	Subtotal ($P2 = 98.2\%$, p = 0.00)		0.32 (0.06, 0.65)	19.84
			0.04 /0.40 0.44	100.00
	Overall ($P2 = 97.28\%$, p = 0.00);		0.31 (0.19, 0.44)	100.00
0 .1 .2 .3 .4 .5 .6 .7 .8 .9 1		<u> </u>		
Proportion	0		.8 .9 1	



Study		ES (95% CI)
Anne Kimball (2020)		0.17 (0.09, 0.27)
COVID-19 Team (2020)		0.91 (0.76, 0.98)
Chengfeng Qiu (2020)	i	0.05 (0.02, 0.11)
Daihie He (2020)		0.16 (0.11, 0.22)
Farida Ismail Al Hosani (2020)		0.91 (0.76, 0.98)
Feng Ye (2020)		0.40 (0.05, 0.85)
G.u. Kim (2020)		0.19 (0.14, 0.25)
Guoaing Qian (2020)		0.13 (0.00, 0.53)
Guosheng Yin (2020)		0.16 (0.11, 0.22)
Haiyan Qiu (2020)		0.28 (0.14, 0.45)
Heng Meng (2020)		— 1.00 (0.94, 1.00)
Jasper Fuk-woochan (2020)		0.17 (0.00, 0.64)
Jose Lucar (2020)		1.00 (0.03, 1.00)
Justin WONG (2020)		0.12 (0.07, 0.18)
Kenji Mizumoto (2020)		0.51 (0.47, 0.55)
Ming chen (2020)		0.33 (0.01, 0.91)
Ren Wan (2020)		0.03 (0.00, 0.09)
Rui Zhou (2020)		— 1.00 (0.89, 1.00)
Shin Young Park (2020)		0.04 (0.01, 0.10)
Shubia Lu (2020)		1.00 (0.29, 1.00)
Sijia Tian (2020)	- :	0.05 (0.03, 0.08)
Thi Quynh Mai Le (2020)		0.14 (0.00, 0.58)
Vera Schoierzeck (2020)		0.04 (0.01, 0.14)
Wei Fang Kong (2020)		0.20 (0.16, 0.23)
Xin Tan (2020)		0.15 (0.02, 0.45)
Yan Bai (2020)		0.17 (0.00, 0.64)
Zhiliang Hu (2020)		0.29 (0.13, 0.51)
LR test: RE vs FE Model chi^2 = 129.9,	p = 0.000	0.25 (0.17, 0.35)
	0 .1 .2 .3 .4 .5 .6	.7 .8 .9 1
	Proportion	

Figure 4: Forest plot: Random Effect and Fixed Effect of Asymptomatic positivity of COVID-19 among population